1. Home
  2. RYOJ vs SCYX Comparison

RYOJ vs SCYX Comparison

Compare RYOJ & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

RYOJ

rYojbaba Co. Ltd.

N/A

Current Price

$2.41

Market Cap

34.8M

ML Signal

N/A

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.84

Market Cap

41.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYOJ
SCYX
Founded
2015
1999
Country
Japan
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
34.8M
41.6M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
RYOJ
SCYX
Price
$2.41
$0.84
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$3.00
AVG Volume (30 Days)
31.4K
275.0K
Earning Date
12-15-2025
03-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.36
EPS
N/A
N/A
Revenue
N/A
$257,000.00
Revenue This Year
N/A
$274.40
Revenue Next Year
N/A
N/A
P/E Ratio
$19.04
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.81
$0.57
52 Week High
$11.43
$1.29

Technical Indicators

Market Signals
Indicator
RYOJ
SCYX
Relative Strength Index (RSI) 42.17 49.26
Support Level $1.89 $0.68
Resistance Level $2.39 $0.88
Average True Range (ATR) 0.21 0.06
MACD 0.03 -0.01
Stochastic Oscillator 22.47 29.31

Price Performance

Historical Comparison
RYOJ
SCYX

About RYOJ rYojbaba Co. Ltd.

rYojbaba Co Ltd is engaged in improving and restoring physical and mental health diminished by work-related stress through consulting and health services. The company provides consulting services to labor unions and companies wishing to build constructive relationships with labor unions and health services to osteopathic clinics and osteopathic beauty salons to alleviate physical ailments created by work-related stress.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: